Connor, Clark & Lunn Investment Management (CC&L)
EW icon

Connor, Clark & Lunn Investment Management (CC&L)’s Edwards Lifesciences EW Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-407,842
Closed -$32.7M – 1681
2026
Q1 		$32.7M Sell
407,842
-279,249
-41% -$23M 0.08% 228
2025
Q4 		$58.6M Buy
687,091
+144,250
+27% +$11.8M 0.15% 131
2025
Q3 		$42.2M Buy
542,841
+494,252
+1,017% +$38.6M 0.13% 147
2025
Q2 		$3.8M Buy
+48,589
New +$3.62M 0.01% 663
2025
Q1 		– Sell
-380,103
Closed -$28.1M – 1474
2024
Q4 		$28.1M Buy
380,103
+166,403
+78% +$11.6M 0.13% 128
2024
Q3 		$14.1M Buy
213,700
+51,896
+32% +$3.77M 0.07% 215
2024
Q2 		$14.9M Buy
161,804
+157,043
+3,299% +$13.9M 0.06% 226
2024
Q1 		$455K Sell
4,761
-270,756
-98% -$22.7M ﹤0.01% 1139
2023
Q4 		$21M Sell
275,517
-245,912
-47% -$17.1M 0.1% 169
2023
Q3 		$36.1M Buy
521,429
+333,841
+178% +$26.8M 0.19% 103
2023
Q2 		$17.7M Buy
187,588
+157,703
+528% +$13.7M 0.09% 171
2023
Q1 		$2.47M Sell
29,885
-288,880
-91% -$22.7M 0.01% 509
2022
Q4 		$23.8M Buy
318,765
+246,991
+344% +$19M 0.14% 121
2022
Q3 		$5.93M Sell
71,774
-10,196
-12% -$981K 0.04% 289
2022
Q2 		$7.79M Sell
81,970
-1,674
-2% -$173K 0.05% 232
2022
Q1 		$9.85M Buy
+83,644
New +$9.38M 0.05% 225
2021
Q4 		– Sell
-235,227
Closed -$26.6M – 1117
2021
Q3 		$26.6M Sell
235,227
-19,536
-8% -$2.23M 0.14% 127
2021
Q2 		$26.4M Buy
254,763
+81,374
+47% +$7.67M 0.13% 143
2021
Q1 		$14.5M Buy
173,389
+135,836
+362% +$11.5M 0.08% 185
2020
Q4 		$3.43M Sell
37,553
-17,622
-32% -$1.46M 0.02% 407
2020
Q3 		$4.4M Buy
+55,175
New +$4.31M 0.03% 332
2020
Q2 		– Sell
-61,500
Closed -$3.87M – 1062
2020
Q1 		$3.87M Buy
+61,500
New +$4.44M 0.03% 292
2015
Q3 		– Sell
-42,750
Closed -$1.01M – 746
2015
Q2 		$1.01M Sell
42,750
-146,850
-77% -$3.31M 0.01% 338
2015
Q1 		$4.5M Buy
189,600
+14,400
+8% +$323K 0.04% 158
2014
Q4 		$3.72M Buy
175,200
+37,200
+27% +$747K 0.03% 177
2014
Q3 		$2.35M Buy
+138,000
New +$2.18M 0.02% 197

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s EW Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Edwards Lifesciences (EW) in Q2 2026, closing a stake of 407,842 shares — an estimated $32.7M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in EW in Q3 2014 and held it in 26 quarters. The position peaked at $58.6M in Q4 2025. 1,325 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Edwards Lifesciences position as of Q2 2026 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 407,842 Edwards Lifesciences shares in Q2 2026, an estimated $32.7M.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Edwards Lifesciences in Q3 2014 and held it in 26 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Edwards Lifesciences position peaked at $58.6M in Q4 2025.
  • 1,325 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.